Prometheus Biosciences (RXDX) Income Statement (2021 - 2023)
Income Statement report data from Mar 31, 2021 to Mar 31, 2023 for Prometheus Biosciences (RXDX).
Reported currency: USD
| Mar 31, 2023 | Dec 31, 2022 | Jun 30, 2022 | Mar 31, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 1.11M (+70.77%) | 650K (-48.82%) | 1.27M (-67.60%) | 3.92M (0.00%) | 3.92M (+276.92%) | 1.04M (+2.97%) | 1.01M (+206.06%) | 330K (-56.58%) | 760K |
Gross Profit | 1.11M (+70.77%) | 650K (-48.82%) | 1.27M (-67.60%) | 3.92M (0.00%) | 3.92M (+276.92%) | 1.04M (+2.97%) | 1.01M (+206.06%) | 330K (-56.58%) | 760K |
Operating Expenses | |||||||||
Research And Development | 36M (+21.64%) | 30M (+15.51%) | 26M (-7.20%) | 28M (0.00%) | 28M (+18.55%) | 24M (+34.25%) | 18M (+29.52%) | 14M (+74.61%) | 7.76M |
Selling General And Administrative | 13M (+11.21%) | 12M (+29.18%) | 9.32M (+15.20%) | 8.09M (0.00%) | 8.09M (+9.03%) | 7.42M (-27.61%) | 10M (+82.38%) | 5.62M (+7.66%) | 5.22M |
Operating Expenses | 50M (+18.65%) | 42M (+19.13%) | 35M (-2.17%) | 36M (0.00%) | 36M (+16.27%) | 31M (+11.44%) | 28M (+45.02%) | 19M (+47.69%) | 13M |
Operating Income | |||||||||
Operating Income | -48.70M (+17.83%) | -41.33M (+21.67%) | -33.97M (+5.83%) | -32.10M (0.00%) | -32.10M (+7.21%) | -29.94M (+11.76%) | -26.79M (+42.12%) | -18.85M (+54.26%) | -12.22M |
EBITDA | -48.47M (+17.87%) | -41.12M (+21.62%) | -33.81M (+5.62%) | -32.01M (0.00%) | -32.01M (+7.20%) | -29.86M (+11.79%) | -26.71M (+42.15%) | -18.79M (+54.27%) | -12.18M |
Other Income / Expenses | |||||||||
Interest Income | 7.83M (+204.67%) | 2.57M (+703.13%) | 320K (+966.67%) | 30K (0.00%) | 30K (0.00%) | 30K (0.00%) | 30K (-25.00%) | 40K (+100.00%) | 20K |
Interest Expense | - | - | - | - | - | - | -10.00K (-94.74%) | -190.00K (-71.21%) | -660.00K |
Net Interest Income | 7.83M (+204.67%) | 2.57M (+703.13%) | 320K (+966.67%) | 30K (0.00%) | 30K (0.00%) | 30K (-25.00%) | 40K (-82.61%) | 230K (-66.18%) | 680K |
Other Non Operating Income | - | - | - | - | - | - | -550.00K | - | -1.08M |
Net Income | |||||||||
Income Before Tax | -40.88M (+5.47%) | -38.76M (+15.19%) | -33.65M (+4.93%) | -32.07M (0.00%) | -32.07M (+7.19%) | -29.92M (+9.48%) | -27.33M (+43.84%) | -19.00M (+36.30%) | -13.94M |
Net Income From Continuing Operations | -40.88M (+5.47%) | -38.76M (+15.19%) | -33.65M (+4.93%) | -32.07M (0.00%) | -32.07M (+7.19%) | -29.92M (+9.48%) | -27.33M (+43.84%) | -19.00M (+36.30%) | -13.94M |
Net Income | -40.88M (+5.47%) | -38.76M (+15.19%) | -33.65M (+4.93%) | -32.07M (0.00%) | -32.07M (+7.19%) | -29.92M (+9.48%) | -27.33M (+43.84%) | -19.00M (+36.30%) | -13.94M |